比亞迪(01211.HK)及中信証券(06030.HK)投資鋰電池溶劑NMP生產商
企查查APP顯示,重慶市中潤化學有限公司發生工商變更,新增比亞迪(01211.HK)、中信証券(06030.HK)等多名股東。
企查查信息顯示,中潤化學是一家鋰電池溶劑NMP生產商,公司成立於2016年,法定代表人為丁龍奇,註冊資本1.9億元人民幣,經營範圍包含:N-甲基(口比)咯烷酮合成生產、銷售;N-甲基(口比)咯烷酮有機溶劑的回收、加工、資源再利用;鋰電池材料的技術研發、生產、銷售等。(ca/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.